CA 125 Blood Test for Early Detection of Ovarian Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking SERMS (like tamoxifen or aromatase inhibitors), you are not excluded from participating.
What data supports the effectiveness of this treatment for early detection of ovarian cancer?
Monitoring CA-125 levels over time can help detect ovarian cancer early, as it has shown a high specificity of 99.6% when used in serial measurements. However, its sensitivity is limited, and it may not detect all early-stage cancers, so it is most effective when combined with other screening methods.12345
Is the CA 125 blood test safe for humans?
How does the CA 125 blood test differ from other treatments for ovarian cancer?
The CA 125 blood test is unique because it is not a treatment but a diagnostic tool used to detect ovarian cancer by measuring the level of a specific protein in the blood. Unlike treatments that aim to cure or manage the disease, this test helps in early detection, although it is not always reliable for all women, especially those with early-stage cancer or certain subtypes.1112131415
What is the purpose of this trial?
The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.
Research Team
Denise Nebgen, MD, PHD
Principal Investigator
The University of Texas MD Anderson Cancer Center
Eligibility Criteria
This trial is for women aged 50-75 who are postmenopausal, have at least one ovary, and haven't had cancer or cancer treatments in the last year. Participants must be willing to take annual blood tests and possibly a transvaginal ultrasound if needed. They should not have conditions preventing informed consent, both ovaries removed, high genetic risk for ovarian cancer, or active non-ovarian malignancies.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment
Participants have blood drawn for CA-125 and other tumor markers, and complete medical and symptom questionnaires
Monitoring
Participants return for blood tests and possibly a transvaginal ultrasound based on CA-125 levels
Follow-up
Participants are monitored for safety and effectiveness after initial assessments and interventions
Treatment Details
Interventions
- Questionnaire
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Golfers Against Cancer
Collaborator